Serum Phospholipid Fatty Acids and Mammographic Density in Premenopausal Women.

DDM-Madrid biomarkers breast cancer breast density desaturation index epidemiology fat fatty acids premenopause

Journal

The Journal of nutrition
ISSN: 1541-6100
Titre abrégé: J Nutr
Pays: United States
ID NLM: 0404243

Informations de publication

Date de publication:
01 09 2020
Historique:
received: 21 01 2020
revised: 26 02 2020
accepted: 19 05 2020
pubmed: 26 6 2020
medline: 17 12 2020
entrez: 26 6 2020
Statut: ppublish

Résumé

The role of fatty acids (FAs) on mammographic density (MD) is unclear, and available studies are based on self-reported dietary intake. This study assessed the association between specific serum phospholipid fatty acids (PLFAs) and MD in premenopausal women. The cross-sectional study DDM-Madrid recruited 1392 Spanish premenopausal women, aged 39-50 y, who attended a screening in a breast radiodiagnosis unit of Madrid City Council. Women completed lifestyle questionnaires and FFQs. Percentage MD was estimated using a validated computer tool (DM-Scan), and serum PLFA percentages were measured by GC-MS. Multivariable linear regression models were used to quantify the association of FA tertiles with MD. Models were adjusted for age, education, BMI, waist circumference, parity, oral contraceptive use, previous breast biopsies, and energy intake, and they were corrected for multiple testing. Women in the third tertile of SFAs showed significantly higher MD compared with those in the first tertile (βT3vsT1 = 7.53; 95% CI: 5.44, 9.61). Elevated relative concentrations of palmitoleic (βT3vsT1 = 3.12; 95% CI: 0.99, 5.25) and gondoic (βT3vsT1 = 2.67; 95% CI: 0.57, 4.77) MUFAs, as well as high relative concentrations of palmitelaidic (βT3vsT1 = 5.22; 95% CI: 3.15, 7.29) and elaidic (βT3vsT1 = 2.69; 95% CI: 0.59, 4.79) trans FAs, were also associated with higher MD. On the contrary, women with elevated relative concentrations of n-6 (ω-6) linoleic (βT3vsT1 = -5.49; 95% CI; -7.62, -3.35) and arachidonic (βT3vsT1 = -4.68; 95% CI: -6.79, -2.58) PUFAs showed lower MD. Regarding desaturation indices, an elevated palmitoleic to palmitic ratio and a low ratio of oleic to steric and arachidonic to dihomo-γ-linolenic acids were associated with higher MD. Spanish premenopausal women with high relative concentrations of most SFAs and some MUFAs and trans FAs showed an increased MD, whereas those with high relative concentrations of some n-6 PUFAs presented lower density. These results, which should be confirmed in further studies, underscore the importance of analyzing serum FAs individually.

Sections du résumé

BACKGROUND
The role of fatty acids (FAs) on mammographic density (MD) is unclear, and available studies are based on self-reported dietary intake.
OBJECTIVES
This study assessed the association between specific serum phospholipid fatty acids (PLFAs) and MD in premenopausal women.
METHODS
The cross-sectional study DDM-Madrid recruited 1392 Spanish premenopausal women, aged 39-50 y, who attended a screening in a breast radiodiagnosis unit of Madrid City Council. Women completed lifestyle questionnaires and FFQs. Percentage MD was estimated using a validated computer tool (DM-Scan), and serum PLFA percentages were measured by GC-MS. Multivariable linear regression models were used to quantify the association of FA tertiles with MD. Models were adjusted for age, education, BMI, waist circumference, parity, oral contraceptive use, previous breast biopsies, and energy intake, and they were corrected for multiple testing.
RESULTS
Women in the third tertile of SFAs showed significantly higher MD compared with those in the first tertile (βT3vsT1 = 7.53; 95% CI: 5.44, 9.61). Elevated relative concentrations of palmitoleic (βT3vsT1 = 3.12; 95% CI: 0.99, 5.25) and gondoic (βT3vsT1 = 2.67; 95% CI: 0.57, 4.77) MUFAs, as well as high relative concentrations of palmitelaidic (βT3vsT1 = 5.22; 95% CI: 3.15, 7.29) and elaidic (βT3vsT1 = 2.69; 95% CI: 0.59, 4.79) trans FAs, were also associated with higher MD. On the contrary, women with elevated relative concentrations of n-6 (ω-6) linoleic (βT3vsT1 = -5.49; 95% CI; -7.62, -3.35) and arachidonic (βT3vsT1 = -4.68; 95% CI: -6.79, -2.58) PUFAs showed lower MD. Regarding desaturation indices, an elevated palmitoleic to palmitic ratio and a low ratio of oleic to steric and arachidonic to dihomo-γ-linolenic acids were associated with higher MD.
CONCLUSIONS
Spanish premenopausal women with high relative concentrations of most SFAs and some MUFAs and trans FAs showed an increased MD, whereas those with high relative concentrations of some n-6 PUFAs presented lower density. These results, which should be confirmed in further studies, underscore the importance of analyzing serum FAs individually.

Identifiants

pubmed: 32584993
pii: S0022-3166(22)02298-2
doi: 10.1093/jn/nxaa168
doi:

Substances chimiques

Fatty Acids 0
Phospholipids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2419-2428

Informations de copyright

Copyright © The Author(s) on behalf of the American Society for Nutrition 2020.

Auteurs

Virginia Lope (V)

Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.

María Del Pilar Del Pozo (MDP)

Department of Preventive Medicine, Public Health, and Microbiology, Autonomous University of Madrid, Madrid, Spain.

Inmaculada Criado-Navarro (I)

Department of Analytical Chemistry, Annex Marie Curie Building, Campus of Rabanales, University of Cordoba, Cordoba, Spain.
Maimónides Institute of Biomedical Research, Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain.

Beatriz Pérez-Gómez (B)

Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.

Roberto Pastor-Barriuso (R)

Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.

Emma Ruiz (E)

Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.

Adela Castelló (A)

Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.
Faculty of Medicine, University of Alcalá, Alcalá de Henares, Madrid, Spain.

Pilar Lucas (P)

Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.

Ángeles Sierra (Á)

Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.

Dolores Salas-Trejo (D)

Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.
Valencian Breast Cancer Screening Program, General Directorate of Public Health, Valencia, Spain.
Center for Public Health Research CSISP, FISABIO, Valencia, Spain.

Rafael Llobet (R)

Institute of Computer Technology, Polytechnic University of Valencia, Valencia, Spain.

Inmaculada Martínez (I)

Valencian Breast Cancer Screening Program, General Directorate of Public Health, Valencia, Spain.
Center for Public Health Research CSISP, FISABIO, Valencia, Spain.

Isabelle Romieu (I)

Center for Research on Population Health, National Institute of Public Health, Cuernavaca, Mexico.
Huber Department of Global Health, Emory University, Atlanta, GA, USA.

Véronique Chajès (V)

Section of Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France.

Feliciano Priego-Capote (F)

Department of Analytical Chemistry, Annex Marie Curie Building, Campus of Rabanales, University of Cordoba, Cordoba, Spain.
Maimónides Institute of Biomedical Research, Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain.

Marina Pollán (M)

Cancer and Environmental Epidemiology Unit, Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Consortium for Biomedical Research in Epidemiology & Public Health, CIBERESP, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH